{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:15:18Z","timestamp":1784621718459,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013132","name":"Mundipharma Pte Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.conctc.2022.101036","type":"journal-article","created":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T15:11:30Z","timestamp":1668352290000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone\/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-1219","authenticated-orcid":false,"given":"Aaron K.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Grobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0830-4864","authenticated-orcid":false,"given":"Brian","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2022.101036_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2011.06.002","article-title":"End-of-life care across Southern Europe: a critical review of cultural similarities and differences between Italy, Spain and Portugal","volume":"82","author":"Me\u00f1aca","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.conctc.2022.101036_bib2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"Patijn","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.conctc.2022.101036_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/IJPC.IJPC_82_17","article-title":"Quality of life among cancer patients","volume":"23","author":"Nayak","year":"2017","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.conctc.2022.101036_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.conctc.2022.101036_bib5","series-title":"Opioid Harm in Australia: and Comparisons between Australia and Canada","year":"2018"},{"key":"10.1016\/j.conctc.2022.101036_bib6","series-title":"Narcotic Drugs: Estimated World Requirements for 2021","year":"2020"},{"key":"10.1016\/j.conctc.2022.101036_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bcp.13026","article-title":"Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated","volume":"82","author":"Gisev","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.conctc.2022.101036_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2022.101036_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/13543784.16.2.181","article-title":"Treatment of opioid-induced gut dysfunction","volume":"16","author":"Holzer","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.conctc.2022.101036_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0269216311401948","article-title":"A systematic review of oxycodone in the management of cancer pain","volume":"25","author":"King","year":"2011","journal-title":"Palliat. Med."},{"key":"10.1016\/j.conctc.2022.101036_bib11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","article-title":"Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden","volume":"61","author":"Panchal","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.conctc.2022.101036_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/papr.12646","article-title":"Oral prolonged-release oxycodone\/naloxone for managing pain and opioid-induced constipation: a review of the evidence","volume":"18","author":"Morlion","year":"2018","journal-title":"Pain Pract."},{"key":"10.1016\/j.conctc.2022.101036_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0885-3924(02)00424-4","article-title":"Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation","volume":"24","author":"Choi","year":"2002","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.conctc.2022.101036_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CP201646","article-title":"Low absolute bioavailability of oral naloxone in healthy subjects","volume":"50","author":"Smith","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.conctc.2022.101036_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0269216311418869","article-title":"A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain","volume":"26","author":"Ahmedzai","year":"2012","journal-title":"Palliat. Med."},{"key":"10.1016\/j.conctc.2022.101036_bib16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/nmo.12463","article-title":"Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials","volume":"26","author":"Blagden","year":"2014","journal-title":"Neuro Gastroenterol. Motil."},{"issue":"1","key":"10.1016\/j.conctc.2022.101036_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S106025","article-title":"Long-term efficacy and safety of oxycodone\u2013naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study","author":"Guerriero","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.conctc.2022.101036_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1742-1241.2010.02360.x","article-title":"Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain","volume":"64","author":"Sandner-Kiesling","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.conctc.2022.101036_bib19","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1185\/03007990802584454","article-title":"Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain","volume":"24","author":"Simpson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.conctc.2022.101036_bib20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jpain.2008.06.014","article-title":"Original report: analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain","volume":"9","author":"Vondrackova","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.conctc.2022.101036_bib21","series-title":"Australian Public Assessment Report for Oxycodone Hydrochloride\/Naloxone Hydrochloride","author":"Goods Administration","year":"2010"},{"key":"10.1016\/j.conctc.2022.101036_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.conctc.2022.101036_bib23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.7150\/jca.24217","article-title":"Hepatotoxicity in advanced lung adenocarcinoma: a retrospective study of 2108 cases","volume":"9","author":"Qian","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.conctc.2022.101036_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.conctc.2022.101036_bib25","article-title":"Oxycodone\/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: challenges in the context of hepatic impairment","author":"Le","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2022.101036_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14123","article-title":"Bisacodyl: a review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation","author":"Corsetti","year":"2021","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.conctc.2022.101036_bib27","first-page":"176","article-title":"Cut points for mild, moderate, and severe pain among cancer and non-cancer patients: a literature review","volume":"4","author":"Woo","year":"2015","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.conctc.2022.101036_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s41927-020-00157-0","article-title":"The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions","volume":"4","author":"Deslauriers","year":"2020","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.conctc.2022.101036_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.conctc.2022.101036_bib30","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ejp.1050","article-title":"Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180\/90 mg daily) \u2013 results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study","volume":"21","author":"Dupoiron","year":"2017","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.conctc.2022.101036_bib31","first-page":"129","article-title":"Pain assessment: global use of the Brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med., Singapore"},{"key":"10.1016\/j.conctc.2022.101036_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpain.2004.11.007","article-title":"The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research","volume":"6","author":"Bennett","year":"2005","journal-title":"J. Pain"},{"key":"10.1016\/j.conctc.2022.101036_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/03007995.2012.657301","article-title":"The Bowel Function Index: a new validated scale for assessing opioid-induced constipation","volume":"28","author":"Ducrott\u00e9","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.conctc.2022.101036_bib34","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.conctc.2022.101036_bib35","article-title":"Oxycodone for cancer-related pain","volume":"8","author":"Schmidt-Hansen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.conctc.2022.101036_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-684X-4-7","article-title":"The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]","volume":"4","author":"Abernethy","year":"2005","journal-title":"BMC Palliat. Care"},{"key":"10.1016\/j.conctc.2022.101036_bib37","article-title":"Fool's gold? Why blinded trials are not always best","volume":"368","author":"Anand","year":"2020","journal-title":"BMJ (Clinical research ed)"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:06:21Z","timestamp":1762520781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865422001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S2451865422001533"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2022.101036","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone\/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2022.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}